



Clinical trial results: Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)

Summary

EudraCT number	2017-003836-35
Trial protocol	ES BE IT
Global end of trial date	23 June 2023

Results information

Result version number	v1 (current)
This version publication date	16 February 2025
First version publication date	16 February 2025

Trial information

Trial identification

Sponsor protocol code	2017-001-COPAF
-----------------------	----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03310125
WHO universal trial number (UTN)	U1111-1201-2656

Notes:

Sponsors

Sponsor organisation name	Population Health Research Institute
Sponsor organisation address	237 Barton Street East, Hamilton, Canada, L8L 2X2
Public contact	COP-AF Project Office, Population Health Research Institute, copaf@phri.ca
Scientific contact	Dr. David Conen, Population Health Research Institute, david.conen@phri.ca

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 August 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	01 June 2023
Global end of trial reached?	Yes
Global end of trial date	23 June 2023
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To determine whether the administration of colchicine compared with placebo reduces the occurrence of 1) perioperative atrial fibrillation/atrial flutter (AF), and 2) myocardial injury after noncardiac surgery (MINS), both within 14 days of randomization.

Protection of trial subjects:

A data and safety monitoring committee performed two interim efficacy analyses for the original primary outcome of clinically important perioperative atrial fibrillation, when 50% and 75% of the original 14-day data were available.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	14 February 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 765
Country: Number of subjects enrolled	Austria: 110
Country: Number of subjects enrolled	Belgium: 24
Country: Number of subjects enrolled	Italy: 287
Country: Number of subjects enrolled	Canada: 1333
Country: Number of subjects enrolled	China: 196
Country: Number of subjects enrolled	Colombia: 54
Country: Number of subjects enrolled	Malaysia: 28
Country: Number of subjects enrolled	Pakistan: 25
Country: Number of subjects enrolled	Switzerland: 32
Country: Number of subjects enrolled	United States: 355
Worldwide total number of subjects	3209
EEA total number of subjects	1186

Notes:

Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1060
From 65 to 84 years	2129
85 years and over	20

Subject disposition

Recruitment

Recruitment details:

Between Feb 14, 2018, and June 27, 2023, we screened 15 368 patients, of whom 7969 were eligible for COP-AF. Of these, 3209 patients provided informed consent and were randomly assigned to receive colchicine (n=1608) or matching placebo (n=1601).

Pre-assignment

Screening details:

Between Feb 14, 2018, and June 27, 2023, we screened 15 368 patients, of whom 7969 were eligible for COP-AF. 3209 patients provided informed consent and were randomly assigned to receive colchicine (n=1608) or matching placebo (n=1601). One patient declined follow-up before the final visit, follow up was more than 99.9% complete.

Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Blinding implementation details:

Eligible patients who provided written informed consent were randomly assigned in a 1:1 ratio to colchicine 0.5 mg twice daily or matching placebo. Patients, health-care providers, data collectors, data managers, and outcome adjudicators were masked to study drug allocation. We used a central, computerised, web-based randomisation system to allocate patients to colchicine or placebo. Randomisation was stratified by centre with variable block sizes unknown to study personnel.

Arms

Are arms mutually exclusive?	Yes
Arm title	Active Colchicine

Arm description:

Oral colchicine 0.5 mg twice daily, starting within 4 h before surgery and continuing for 10 days.

Arm type	Experimental
Investigational medicinal product name	Colchicine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral colchicine 0.5 mg twice daily, starting within 4 h before surgery and continuing for 10 days.

Arm title	Active Placebo
------------------	----------------

Arm description:

Oral placebo 0.5 mg twice daily, starting within 4 h before surgery and continuing for 10 days.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral placebo 0.5 mg twice daily, starting within 4 h before surgery and continuing for 10 days.

Number of subjects in period 1	Active Colchicine	Active Placebo
Started	1608	1601
Completed	1608	1601

Baseline characteristics

Reporting groups

Reporting group title	Active Colchicine
Reporting group description:	
Oral colchicine 0.5 mg twice daily, starting within 4 h before surgery and continuing for 10 days.	
Reporting group title	Active Placebo
Reporting group description:	
Oral placebo 0.5 mg twice daily, starting within 4 h before surgery and continuing for 10 days.	

Reporting group values	Active Colchicine	Active Placebo	Total
Number of subjects	1608	1601	3209
Age categorical			
Units: Subjects			
Adults (18-64 years)	536	524	1060
From 65-84 years	1063	1066	2129
85 years and over	9	11	20
Age continuous			
Units: years			
arithmetic mean	68.3	68.3	
standard deviation	± 7.3	± 7.1	-
Gender categorical			
Units: Subjects			
Female	777	776	1553
Male	831	825	1656
Medical history: Stroke			
Units: Subjects			
Yes	46	39	85
No	1562	1562	3124
Medical history: Myocardial infarction			
Units: Subjects			
Yes	90	73	163
No	1518	1528	3046
Medical history: Hypertension			
Units: Subjects			
Yes	836	832	1668
No	772	769	1541
Medications taken within 24 h before surgery: Aspirin			
Units: Subjects			
Yes	155	141	296
No	1453	1460	2913
Medications taken within 24 h before surgery: ACE inhibitor or ARB			
Units: Subjects			
Yes	310	305	615
No	1298	1296	2594
Medications taken within 24 h before surgery: Rate-controlling calcium channel blocker			

Units: Subjects			
Yes	28	23	51
No	1580	1578	3158
Type of surgery: Wedge resection Units: Subjects			
Yes	314	337	651
No	1294	1264	2558
Type of surgery: Segment resection Units: Subjects			
Yes	245	242	487
No	1363	1359	2722
Type of surgery: Lobe resection Units: Subjects			
Yes	1029	1013	2042
No	579	588	1167
Type of surgery: Pneumonectomy Units: Subjects			
Yes	44	44	88
No	1564	1557	3121
Type of surgery: Decortication Units: Subjects			
Yes	60	58	118
No	1548	1543	3091
Type of surgery: Mediastinal mass resection Units: Subjects			
Yes	88	91	179
No	1520	1510	3030
Type of surgery: Pericardium resected Units: Subjects			
Yes	24	23	47
No	1584	1578	3162
Type of surgery: Other Units: Subjects			
Yes	363	358	721
No	1245	1243	2488

End points

End points reporting groups

Reporting group title	Active Colchicine
Reporting group description: Oral colchicine 0.5 mg twice daily, starting within 4 h before surgery and continuing for 10 days.	
Reporting group title	Active Placebo
Reporting group description: Oral placebo 0.5 mg twice daily, starting within 4 h before surgery and continuing for 10 days.	

Primary: Coprimary outcomes

End point title	Coprimary outcomes
End point description:	
End point type	Primary
End point timeframe: >	

End point values	Active Colchicine	Active Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1608	1601		
Units: subjects				
Clinically important perioperative AF	103	120		
MI after non-cardiac surgery	295	325		

Statistical analyses

Statistical analysis title	Co-primary outcome #1
Statistical analysis description: Effect of Colchicine versus Placebo on clinically important perioperative atrial fibrillation	
Comparison groups	Active Placebo v Active Colchicine
Number of subjects included in analysis	3209
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.22
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.85

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.65
upper limit	1.1

Statistical analysis title	Co-primary outcome #2
-----------------------------------	-----------------------

Statistical analysis description:

Effect of Colchicine versus Placebo on Myocardial injury after non-cardiac surgery

Comparison groups	Active Colchicine v Active Placebo
Number of subjects included in analysis	3209
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.16
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	1.05

Secondary: Secondary outcomes

End point title	Secondary outcomes
-----------------	--------------------

End point description:

End point type	Secondary
End point timeframe:	
>	

End point values	Active Colchicine	Active Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1608	1601		
Units: subjects	1608	1601		

Statistical analyses

Statistical analysis title	Secondary outcome # 1
-----------------------------------	-----------------------

Statistical analysis description:	
Composite of all-cause death, non-fatal MINS, and non-fatal stroke	
Comparison groups	Active Colchicine v Active Placebo
Number of subjects included in analysis	3209
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.11
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.75
upper limit	1.03

Statistical analysis title	Secondary outcome #2
Statistical analysis description:	
Composite of all-cause death, non-fatal myocardial infarction, and non-fatal stroke	
Comparison groups	Active Colchicine v Active Placebo
Number of subjects included in analysis	3209
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.16
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.39
upper limit	1.17

Statistical analysis title	Secondary outcome #3
Statistical analysis description:	
MINS not fulfilling the fourth universal definition of myocardial infarction	
Comparison groups	Active Colchicine v Active Placebo
Number of subjects included in analysis	3209
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.22
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.9

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	1.06

Statistical analysis title	Secondary outcome #4
Statistical analysis description:	
Myocardial infarction	
Comparison groups	Active Colchicine v Active Placebo
Number of subjects included in analysis	3209
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.69
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.41
upper limit	1.81

Statistical analysis title	Secondary outcome #5
Statistical analysis description:	
Time to chest tube removal, days*	
Comparison groups	Active Colchicine v Active Placebo
Number of subjects included in analysis	3209
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.27
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Secondary outcome #6
Statistical analysis description:	
Days in hospital	
Comparison groups	Active Colchicine v Active Placebo
Number of subjects included in analysis	3209
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.48
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Secondary outcome #7
Statistical analysis description: Nights in step-down unit	
Comparison groups	Active Colchicine v Active Placebo
Number of subjects included in analysis	3209
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.56
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Secondary outcome #8
Statistical analysis description: Nights in intensive care unit	
Comparison groups	Active Colchicine v Active Placebo
Number of subjects included in analysis	3209
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.91
Method	Wilcoxon (Mann-Whitney)

Other pre-specified: Tertiary outcomes

End point title	Tertiary outcomes
End point description:	
End point type	Other pre-specified
End point timeframe:	
>	

End point values	Active Colchicine	Active Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1608	1601		
Units: subjects	1608	1601		

Statistical analyses

Statistical analysis title	Tertiary outcome #1
-----------------------------------	---------------------

Statistical analysis description:	
All-cause death	
Comparison groups	Active Colchicine v Active Placebo
Number of subjects included in analysis	3209
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.35
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.63
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.25
upper limit	1.63

Statistical analysis title	Tertiary outcome #2
Statistical analysis description:	
Deep venous thrombosis or pulmonary embolism	
Comparison groups	Active Colchicine v Active Placebo
Number of subjects included in analysis	3209
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.058
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.97
upper limit	6.44

Statistical analysis title	Tertiary outcome #3
Statistical analysis description:	
Composite of life-threatening or major bleeding	
Comparison groups	Active Colchicine v Active Placebo
Number of subjects included in analysis	3209
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.59
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.9

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	1.33

Statistical analysis title	Tertiary outcome #4
Statistical analysis description:	
Days alive and at home	
Comparison groups	Active Placebo v Active Colchicine
Number of subjects included in analysis	3209
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.99
Method	Wilcoxon (Mann-Whitney)

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

Study personnel followed up patients daily until discharge. Daily cardiac troponin levels were obtained during the first 3 postoperative days. The final follow-up visit occurred 14 days after randomisation; no ECG was mandated at the final follow-up visit

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	25.0

Reporting groups

Reporting group title	Active Colchicine
Reporting group description: -	
Reporting group title	Active Placebo
Reporting group description: -	

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Per protocol, only serious adverse events were required to be reported.

Serious adverse events	Active Colchicine	Active Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	67 / 1608 (4.17%)	66 / 1601 (4.12%)	
number of deaths (all causes)	7	11	
number of deaths resulting from adverse events	0	0	
Vascular disorders			
Aortic dissection			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	3 / 1608 (0.19%)	2 / 1601 (0.12%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Shock			

subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bleeding			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Surgical and medical procedures			
Thoracotomy			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Oedema			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute respiratory distress syndrome			
subjects affected / exposed	1 / 1608 (0.06%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Acute respiratory failure			

subjects affected / exposed	1 / 1608 (0.06%)	3 / 1601 (0.19%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atelectasis			
subjects affected / exposed	1 / 1608 (0.06%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial obstruction			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchospasm			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Emphysema			
subjects affected / exposed	3 / 1608 (0.19%)	2 / 1601 (0.12%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	2 / 1608 (0.12%)	2 / 1601 (0.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	3 / 1608 (0.19%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			

subjects affected / exposed	4 / 1608 (0.25%)	6 / 1601 (0.37%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	5 / 1608 (0.31%)	6 / 1601 (0.37%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
Chylothorax			
subjects affected / exposed	2 / 1608 (0.12%)	3 / 1601 (0.19%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial secretion retention			
subjects affected / exposed	1 / 1608 (0.06%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary air leakage			
subjects affected / exposed	9 / 1608 (0.56%)	12 / 1601 (0.75%)	
occurrences causally related to treatment / all	0 / 9	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Delirium			
subjects affected / exposed	1 / 1608 (0.06%)	2 / 1601 (0.12%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hallucination			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			

Liver function test abnormal subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mycobacterium tuberculosis complex test negative			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Arterial injury			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound dehiscence			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural pain			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasoplegia syndrome			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural hypotension			
subjects affected / exposed	1 / 1608 (0.06%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Cardiac disorders			
Atrioventricular block second degree			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myopericarditis			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis			
subjects affected / exposed	1 / 1608 (0.06%)	2 / 1601 (0.12%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleuropericarditis			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Aphasia			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Dysarthria			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heparin-induced thrombocytopenia			
subjects affected / exposed	2 / 1608 (0.12%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Ileus paralytic			
subjects affected / exposed	2 / 1608 (0.12%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal perforation			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal ulcer perforation			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Hyperbilirubinaemia			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary-bronchial fistula			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Rash pruritic			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Subcutaneous emphysema			
subjects affected / exposed	7 / 1608 (0.44%)	6 / 1601 (0.37%)	
occurrences causally related to treatment / all	0 / 7	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Urinary retention			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute kidney injury			
subjects affected / exposed	0 / 1608 (0.00%)	2 / 1601 (0.12%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Adrenal haemorrhage			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Sepsis			
subjects affected / exposed	1 / 1608 (0.06%)	0 / 1601 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 1608 (0.00%)	1 / 1601 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 3 %

Non-serious adverse events	Active Colchicine	Active Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 1608 (0.00%)	0 / 1601 (0.00%)	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported